RxDoctor Payments Data

Cynthia Blalock, APRN

Gerontology · Nashville, TNNPI 1407251705

Payments from drug & device makers

What this record shows

8 manufacturers reported payments, led by Intuitive Surgical at 45.5% of the total. Reporting peaked in 2024 at $1,509 and has fallen 84.7% since, to $231 in 2025.

$2,669in general payments, 2019–2025

Across 22 payments — averaging $121.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Abbott$590
  • Novo Nordisk$237
  • Amgen$173
  • Evoke Pharma, Inc.$125
  • Mylan Specialty L.p.$121
  • plus $208 from 2 others

What the payments were for

  • Travel & lodging$1,17444%
  • Food & beverage$1,49556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical10$1,216
Abbott4$590
Novo Nordisk2$237
Amgen(2 entities)2$173
Evoke Pharma, Inc.1$125
Mylan Specialty L.p.1$121
Davol Inc.1$106
Corcept Therapeutics1$102

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,669 in reported general payments places this provider in the 85th percentile of 194 gerontology providers in Tennessee.

See all gerontology providers in Tennessee

Medicare billing

Part B allowed, 2024
$19,153
Medicare patients
123
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide152$169,678
OzempicSemaglutide149$169,226
WegovySemaglutide18$24,080
TrulicityDulaglutide14$15,536
Omeprazole62$908
Metformin Hcl ErMetformin Hcl83$786
Ondansetron OdtOndansetron13$266
Topiramate27$244
Promethazine Hcl17$123
Metformin Hcl13$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$237$193,306167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 194 gerontology providers in Tennessee.

Other gerontology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →